Biotech Stock News (SYN) (CNAT)

Synthetic Biologics (NASDAQ:SYN) On February 3, 2016 shares of Synthetic Biologics fell by 14% after the company announced an update on the phase 2 clinical trial treating patients with Relapsing-Remitting Multiple Sclerosis — RRMS. The company’s drug used to treat these patients with RRMS is known as Trimesta. Both the clinical and MRI results of … Read more

Biotech Stock News (RXII) (MRK) (BMY) (CNAT) (ICPT)

Rxi Pharmaceuticals Corp (NASDAQ: RXII) Rxi Pharmaceuticals last week on March 23, 2015 presented at the 73rd Annual Academy of Dermatology in which the company reported ┬ápositive progress on clinical trial updates for its dermatology programs. The clinical trial with RXI-109-1301 phase 2a enrolled patients to be tested for hypertrophic scars on the abdomen only. … Read more